Published in Medical Devices and Surgical Technology Week, August 1st, 2004
According to researchers in Massachusetts, "[i]dentification of antibody targets associated with malignant disease is indispensable to developing passive and active antibody-based therapeutics or diagnostic agents."
To facilitate this process, Y.Y. Huang and colleagues at Framingham-based Genzyme Corporation "developed a novel technique combining Western blotting, genetic profiling, and mass spectroscopy that allows for the rapid and unambiguous identification of such antigens in a high-throughput manner."
"Herein, we demonstrate this technique, designated Ab...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.